Navigation Links
Researchers validate preclinical effectiveness of TB drug target
Date:11/29/2011

Menlo Park, Calif. -- In research at SRI International, scientists evaluating new drug targets against tuberculosis (TB) recently validated the preclinical effectiveness of a target that could rapidly eliminate infections and potentially shorten treatment time. The new drug target is a protein called DNA gyrase B, found in bacteria that cause TB infections.

DNA gyrase is an enzyme consisting of two subunits: gyrase A and gyrase B. Although gyrase A is often the target of antibiotics, such as ciprofloxacin, there currently is no antibiotic on the market that targets gyrase B. In laboratory experiments, SRI researchers found that by targeting gyrase B, TB bacteria are killed whether they are replicating or dormant. Further studies will be conducted toward the development of a TB drug against gyrase B.

"One of the greatest needs in infectious disease treatment is a drug that allows a shorter length of treatment," said Peter Madrid, Ph.D., program director in the Center for Infectious Disease and Biodefense Research, SRI Biosciences Division. "Though our program is still in the preclinical phase of research, with a number of years of required testing ahead, our goal is to develop a drug that will improve the treatment process for TB patients."

TB patients currently undergo treatment for six months and take a combination of at least four different drugs. There are often challenges to treatment effectiveness because of the long treatment time, including low patient treatment compliance and high rates of drug resistance. Tuberculosis that is resistant to multiple drugs takes even longer to treat, usually 18 to 24 months.


'/>"/>
Contact: Dina Basin
dina.basin@sri.com
650-859-3845
SRI International
Source:Eurekalert

Page: 1

Related medicine news :

1. Researchers surprised to find fatty liver disease poses no excess risk for death
2. Moffitt Cancer Center researchers find men less willing to be screened for cancer
3. MU researchers find synthetic RNA lessens severity of fatal disease
4. Researchers search for culprit behind dry eyes, mouths and more
5. MU researchers develop tool that saves time, eliminates mistakes in diabetes care
6. Researchers discover new way to form extracellular vesicles
7. Researchers discover Achilles heel in lethal form of prostate cancer
8. Jackson Laboratory researchers uncover steps in synapse building, pruning
9. UCLA stem cell researchers uncover mechanism that regulates human pluripotent stem cell metabolism
10. Ben-Gurion University of the Negev researchers achieve male fertility breakthrough
11. Canadian researchers find potential new leukemia treatment with old antibiotic drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... communities in the greater Dallas, Miami, and Raleigh regions, is organizing an extended ... overcome a rare and deadly chromosome abnormality. , After struggling since birth with ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... certification process to promote standards of excellence for the field of eating disorders, ... March 22 – 25, 2018 in Orlando, Florida at the Omni Resort at ...
(Date:10/13/2017)... ... 13, 2017 , ... Many families have long-term insurance that covers care for ... a waiver for care if the client has a cognitive impairment diagnosis. , ... care, is often waived, so the benefits from their insurance start immediately,” said Mechell ...
(Date:10/13/2017)... ... 2017 , ... Talented host, actor Rob Lowe, is introducing ... new episode of "Success Files," which is an award-winning educational program broadcasted on ... subject in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
(Date:9/27/2017)... , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global ... that its MyDario product is expected to appear on The Dr. Oz ... Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked ... The segment features ...
Breaking Medicine Technology: